These findings underscore the critical role of inflammation regulation in the treatment of diabetes, suggesting that modulating the TLR4/NF-κB signaling pathway constitutes an effective therapeutic strategy for DM+MCAO. The gene discussed is NFKB1; the disease is diabetes mellitus.